Skip to main content
logo
DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,705.00
+15.00 (0.41%)
At close: Aug 24, 2026

DongKoo Bio & Pharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
33,01350,2722,03611,8126,6149,327
Depreciation & Amortization
8,2778,9197,2746,0285,6325,054
Loss (Gain) From Sale of Assets
-20.09-3.63-5.980-123.891.33
Asset Writedown & Restructuring Costs
4,7214,721665.56--0
Loss (Gain) From Sale of Investments
-48,298-52,191-7,119-2,0778,869-1,090
Loss (Gain) on Equity Investments
7,657-3,16113,112660.61-118.281,733
Stock-Based Compensation
189.82193.02251.89224.51--
Provision & Write-off of Bad Debts
62.88159.22-193.35-52.8240.44241.76
Other Operating Activities
-3,829-2,3792,2951,697331.91638.04
Change in Accounts Receivable
-618.58-251.85478.4-1,333-2,8611,431
Change in Inventory
24,089-5,950-6,632-12,838-6,686-1,897
Change in Accounts Payable
-8,097-10,2874,389-3,0932,7152,399
Change in Other Net Operating Assets
4,0485,672793.422,5582,40465.1
Operating Cash Flow
21,195-4,28717,3443,58516,81917,903
Operating Cash Flow Growth
--383.75%-78.68%-6.05%139.06%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-21,703-17,656-21,866-13,845-4,978-4,266
Sale of Property, Plant & Equipment
36.253.6460.66300.4411.97
Sale (Purchase) of Intangibles
-1,115-2,796-3,598-2,034-6,098-1,137
Investment in Securities
-4,943-16,096-18,43311,851-16,2876,202
Other Investing Activities
-761.41-639.7583.28-10639-366.43
Investing Cash Flow
-30,805-38,927-45,033-5,133-27,014463.93

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-63,93747,0297,50015,00070.75
Long-Term Debt Issued
-22,5789,8951,447--
Total Debt Issued
70,01086,51556,9248,94715,00070.75
Short-Term Debt Repaid
--42,436-13,528---
Long-Term Debt Repaid
--1,733-935.5-1,126-5,966-742.12
Total Debt Repaid
-45,081-44,168-14,463-1,126-5,966-742.12
Net Debt Issued (Repaid)
24,92842,34742,4617,8219,034-671.37
Repurchase of Common Stock
---3,408-79.9-2,995-1,998
Dividends Paid
-3,245-3,245-3,313-3,038-2,804-942.94
Other Financing Activities
437.81409.831,45449-50-76.1
Financing Cash Flow
22,12139,51237,1944,7523,185-3,688

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
305.92-109.02154.83-4.74-33.91-2.27
Miscellaneous Cash Flow Adjustments
-0-0--0-0
Net Cash Flow
12,816-3,8129,6603,199-7,04314,676

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-507.99-21,944-4,522-10,26011,84113,637
Free Cash Flow Growth
-----13.16%514.06%
Free Cash Flow Margin
-0.21%-9.04%-1.81%-4.76%6.07%8.79%
Free Cash Flow Per Share
-18.30-780.52-166.62-371.44426.63482.57
Levered Free Cash Flow
1,091-35,979-9,684-15,354-140.4310,027
Unlevered Free Cash Flow
3,476-33,786-7,875-14,254509.1410,286

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
3,3833,3032,8281,672902.19362.76
Cash Income Tax Paid
1,3634,3012,7754,1043,0761,392
Change in Working Capital
19,421-10,817-970.91-14,706-4,4271,999